Business & Finance Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
By
· September 21, 2026 · 1 min read
This article was originally published by
CNBC Top News
and is republished here under license.
Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
Related
FT finds thousands of Russian payments handled by Standard Chartered, Citigroup and other international groups in vast leak from inside…
By
· September 21, 2026 · 1 min read
The antitrust lawsuit threatened to delay Paramount's acquisition until mid-2027 and to cost the company hundreds of millions of dollars…
By
· September 21, 2026 · 1 min read
Meta's Muse AI personal agent tool had 730,000 downloads over the roughly five days after its launch.…
By
· September 21, 2026 · 1 min read
Leave a Reply